text:
Chairman, President and CEO, Intarcia Therapeutics, Inc.
Mr. Graves has been Chairman, President and CEO of Intarcia since April 2012, having previously served solely as Executive Chairman of the company since August 2010, and as Acting CEO since October 2011. During his time at Intarcia, his influence on the Company's vision, purpose and values has transformed not only its business goals, but also how it goes about its business. Since he joined, Intarcia successfully raised more than $1 billion in capital through very creative financings and strategic partnerships. Mr. Graves was named the 2015 EY Entrepreneur of the Year in New England, and Intarcia was cited as a "Unicorn" company worth watching in a cover story of Fortune Magazine, and a 2015 "Disruptor 50" company by CNBC. Mr. Graves is a global industry leader with more than twenty years of U.S. and global general management experience at top-tier U.S. and European based pharmaceutical and biotech companies. He has successfully built and managed several of the largest multi-billion dollar franchises in the industry and developed and launched more than 10 blockbuster brands in a broad range of general medicine, specialty and orphan disease areas. In addition to driving dynamic top and bottom-line growth in large global pharmaceutical companies, Mr. Graves also played a key leadership role in building two highly successful early stage companies: Astra Merck Pharmaceuticals and Vertex Pharmaceuticals. Prior to joining Intarcia, Mr. Graves was EVP, Chief Commercial Officer, and Head of Corporate and Strategic Development at Vertex Pharmaceuticals. Before his tenure at Vertex, he spent nearly ten years at Novartis Pharmaceuticals, most recently on the Executive Committee as Global Head of the General Medicines Business Unit & Chief Marketing Officer for the Pharmaceuticals division. Prior to Novartis, Mr. Graves held several commercial and general management positions at Merck and Astra Merck/Astra Pharmaceuticals where he spent most of his time leading the GI Business Unit responsible for Prilosec® and Nexium®. In addition to his current responsibility at Intarcia, Mr. Graves serves as Chairman of the Board of Radius® Health, Inc. (RDUS), and as a Director at Achillion Pharmaceuticals (ACHN), and Seres Therapeutics (MCRB). Mr. Graves earned his B.S. in Biology from Hillsdale College and has attended numerous executive leadership programs at Harvard, Wharton School of Management and University of Michigan.
Dr. Rizk currently serves as President and Chief Executive Officer of Accretive Health. He previously served as president of McKesson Health Solutions, a business unit of McKesson Corporation, and as Senior Partner and Global Director, Medical Management/Pharmacy for Deloitte Consulting. He led the company's medical cost and quality management practice. Previous to that, he held a variety of roles at Monsanto Corporation, serving as Associate Medical Director, Corporate Medical and Scientific Affairs and then Worldwide Medical Director. Dr. Rizk was formerly a member of the board of DMAA: Care Continuum Alliance and currently serves on the boards of directors of the National Association for Hispanic Health, Manage Care Editorial, Accuray Inc. and Accretive Health. A Senior Scholar professor at Jefferson Medical College, Dr. Rizk's work has been widely published in medical journals and medical books. His book, The New Era of Healthcare: Practical Strategies for Providers and Payers, focuses on ways that providers and payers can work together to reduce costs while improving efficiency and patient care. In 2013, Modern Physician named Dr. Rizk one of the "50 Most Influential Physician Executives in the United States," the fifth time he has been recognized by this publication. In addition, Modern Healthcare has listed him among the "Top 100 Most Powerful People in Healthcare," while Managed Healthcare Executive named him to its "Top 25 Leaders in Disease Management." Dr. Rizk has frequently lectured at Harvard, MIT, Wharton, Northwestern Kellogg School, and Columbia Business School.
Bryan Roberts joined Venrock, a venture capital investment firm, in 1997, where he serves as partner. From 1989 to 1992, Dr. Roberts worked in the corporate finance department of Kidder, Peabody & Co., a brokerage company. Dr. Roberts is the chairman of Ironwood Pharmaceuticals and serves on the board of directors of ZELTIQ as well as on the board of several other private companies, and he has previously served on the board of directors of athenahealth, Inc., XenoPort, Inc. and Sirna Therapeutics, Inc. He received a B.A. from Dartmouth College and a Ph.D. in chemistry and chemical biology from Harvard University.
Gino Santini is a globally respected pharmaceutical executive, having spent nearly three decades at Eli Lilly and Company where he served in a number of key roles, including as a member of their Executive Committee. His distinguished career began when he joined Lilly as a Financial Planning Associate in Italy in 1983. He went on to serve in financial and marketing roles in Italy and Indianapolis, and also served as Pharmaceutical Director in Belgium, General Manager in Mexico City, Area Director of Latin America, President of Lilly's women's health business, and President of U.S. Operations, before ascending to Senior Vice President of Corporate Strategy and Business Development. In this final role, Mr. Santini led corporate strategy and long-range planning, M&A, new product licensing, innovative financing of internal development projects, and the expansion of Lilly Ventures in the U.S. and China. In addition to Intarcia, Mr. Santini serves on the Boards of Directors of several biopharmaceutical companies and an Italian financial holding company of businesses in the sugar, food, mechanical, and packaging sectors. He serves as an Associate Member of the Board of the National Association of Chain Drug Stores, and previously served as Chairman of the Board of the National Pharmaceutical Council, and as Chairman of the Board of Noble of Indiana, a non-profit agency that serves people with developmental disabilities. He is also a former Director of the United Way, and a former Member of the Executive Committee and Board of the Indianapolis Chamber of Commerce. Fluent in four languages, Mr. Santini holds an undergraduate degree in mechanical engineering from the University of Bologna and an MBA from the Simon School of Business, University of Rochester.
Glen Sato has been a partner in the Life Sciences and Companies practice group at Cooley Godward LLP since January 2006. Prior to that time, he served as Senior Vice President and Chief Financial Officer of PDL BioPharma, Inc. (PDL) from May 2003 to September 2005. He joined PDL from Exelixis, Inc., where he had served as Chief Financial Officer and General Counsel since November 1999. Previous to Exelixis, he served in various legal and strategic planning positions at PDL, most recently as Vice President, Legal and General Counsel. During his tenure at PDL and Exelixis, Mr. Sato was responsible for finance, SEC reporting and compliance, disclosure issues and internal and external business functions, including business development, intellectual property licensing and licensing strategy, general corporate counseling, insider trading compliance and intellectual property protection. He received his Bachelor of Arts from Wesleyan University, and his J.D. and M.B.A. from UCLA.
Irwin Scher, M.D. has served as a member of our board of directors since April 2005. Since March 2005, Dr. Scher has served as the Chief Executive Officer of Biosynexus, Incorporated, a biopharmaceutical company. From January 2002 to January 2005, Dr. Scher served as a full-time development and business consultant to the chief executive officer of Merck KgaA in Darmstadt, Germany, a global pharmaceutical products and services company, while also serving as Vice President, global clinical research and development for Merck KgaA from June 2002 to September 2003. From January 1992 to August 1999, Dr. Scher served as Senior Vice President, Drug Development and Medical Affairs at Astra/Merck, a joint venture of Astra AB and Merck, and AstraZeneca, a global pharmaceutical products company. Dr. Scher is a director of Clarient, Inc. Dr. Scher holds a B.S. in chemistry from the New York State University at Albany and an M.D. from the Albert Einstein College of Medicine. He is board certified in internal medicine and rheumatology.
Nancy Thornberry became a member of the Intarcia Board of Directors in December 2013. Currently, she is the CEO of Kallyope, a biotechnology company. Nancy is a highly regarded expert in pharmaceutical R&D, strategy and portfolio management and has been involved in scientific innovation in diverse areas, which paved the way for significant breakthroughs. This took place during her illustrious 34-year career at Merck Research Laboratories, where she began in 1979 as a Biochemist, and steadily assumed positions of increasing responsibility – distinguishing herself along the way with numerous and significant achievements. Those achievements came early as Nancy provided enzymology support to the angiotensin converting enzyme (ACE) inhibitor project for the treatment of hypertension, and multiple other targets. Her accomplishments also include the identification of the first caspase, interleukin-1β converting enzyme (ICE/caspase-1), and contributions to the discovery of the target of ezetimibe, the active ingredient in ZETIA™. Most notably, she co-led the team that discovered Januvia™ (sitagliptin) in 2001, which is currently the #1 branded oral agent for the treatment of type 2 diabetes, and the largest selling product in Merck history. In 2011 Nancy became SVP and Franchise Head of Diabetes and Endocrinology for Merck Research Laboratories. Also in 2011 Nancy was honored with the PhRMA Discoverers Award. In addition to her prolific publishing record, Nancy has guest lectured at prestigious venues, as well as chaired many key scientific and medical sessions.
At Intarcia, our goal is to develop and commercialize drug therapies that deliver an improved therapeutic outcome while enhancing patients' quality of life.


text:
Ashley has been at Safe Haven for a number of years. She used to be shy but over time, she has started to allow staff and volunteers to pet her, so we know she will do well in a forever home with a gentle, patient owner. Will make a great companion for someone.
Thank You!
Your message has been sent to Safe Haven Animal Sanctuary.
You'll receive a copy, too, at to help you keep track of which pets you've inquired about, and which shelters and rescues you've emailed.
NOTE: Some shelters have physical locations you can visit; some of these shelters may only have pets for a limited time, so please do not wait for a reply—just go visit the shelter! Other organizations are rescue groups run by busy volunteers who may take a while to reply. You can find information about the shelter or rescue group caring for this pet, and their adoption procedures, on the pet's details page on Adopt-a-Pet.com.

subset: commoncrawl


text:
|This article or section needs attention
|This article or section does not adequately cite one of more of its sources, and needs attention. If you can provide references from valid resource material, feel free to edit it to add a citation or correct the data
The Maroan warship was a type of starship used by the Maroan Dominion in the 23rd century.
After a Maroan alliance with the Romulan Star Empire, these ships were later equipped with antiquated Romulan cloaking devices.


text:
Gilani's comments come after US announced a bounty of $10 million on Hafiz Saeed.
Meanwhile, the US steeping its pressure on Pakistan said that it wanted to mete out justice and convict Saeed in the court of law, the mastermind behind the 2008 Mumbai attacks. US maintained that the bounty was not for finding his location.
Meanwhile, the security of the LeT chief and the JuD founder was beefed up following the announcement of bounty.
In a television interview, Saeed mocked at the US and asked it to give him the bounty offered for him under the Rewards for Justice programme.
He also dismissed the allegations levelled against him of his alleged active role in terrorism.
OneIndia News


text: The OrosiValley, southeast of Cartago, is generally considered one of the most beautiful valleys in Costa Rica. The ReventazónRiver meanders through this steep-sided valley until it collects in the lake formed by the Cachí Dam. A well-paved road winds a near-perfect loop around the lake, allowing for easy access to all of the attractions listed below. Scenic overlooks are near the town of Orosi, at the head of the valley, and in Ujarrás, on the banks of the lake.


text:
- Trending Now: More Trending:
- Svengali syzygy hegemon repugnant white nationalist, white supremacist
bale out
Definition of bale out
1 : to jump out of an airplane with a parachute The pilot baled out just before the plane crashed.
2 : to leave or escape a harmful or difficult situation Most investors have baled out of the business.
Word by Word Definitions
: great evil
: woe, sorrow
: a large bundle of goods
: a large closely pressed package of merchandise bound and usually wrapped
: to make up into a bale
: in a direction away from the inside or center
: outside
: from among others
: eject, oust
: to identify publicly as being such secretly
: to identify as being a closet homosexual
: used as a function word to indicate an outward movement
: situated outside : external
: out-of-bounds
: situated at a distance : outlying
: outside
: one who is out of office or power or on the outside
: an act or instance of putting a player out or of being put out in baseball
Seen and Heard
What made you want to look up bale out? Please tell us where you read or heard it (including the quote, if possible).


text:
Email Marketing and Opt In List Building: On Keeping Online Businesses Profitable
Since the advent of the information technology, the Internet had been a valuable commodity to most people. Here, they find ways on how to earn more money even without having to spend more capital on building a business. Nowadays, many business people are realizing the importance of email marketing. Through emails, an online business can market their product directly through their customers. Generally, the main purpose of email marketing is to reach their target audience as quickly and as direct as possible. They need to reach their target market so as to promote their products and services that would benefit their customers. However, some businesses use email marketing in order to maintain their contact and relationship with their customers. The reason why email marketing has grown in such unprecedented rate is based on the fact that people in the virtual community are always hungry for information. They subscribe to information … Continue reading


text:
Great job! :3
Loving the gentle colors and soft textures. Beautiful work.
This is so amazing! Very nice style! I love it!
Astounding color scheme!
The colors are beautiful, your artwork is really amazing
Wonderful choice of colours ! It's so sweet and peaceful
I really like the colours you've used and she is lovely! Good job
just GREAT!
so pretty! *o*
love the soft fluffy colors
Wow! She looks lovely.
Beautiful job on the details and coloring
Wow! The colours and shapes are amazing! I have trouble with paint because I'm not patient enough... Things like this make me want to keep working on it though!